use ai to optimize your pricing strategy and increase revenue ✌️【365vc.net】✌️Small investment, big returns! Start at ₹500 and grow your wealth month by month. use ai to optimize your pricing strategy and increase revenue - AI Investments Steady Growth ✌️【365vc.net】✌️Join the blockchain revolution. ₹500 can unlock massive monthly profits. Start now!

use ai to optimize your pricing strategy and increase revenue ✌️【365vc.net】✌️Small investment, big returns! Start at ₹500 and grow your wealth month by month.Pharmaceutical giant Dr Reddy’s Laboratories (DRL) saw its shares surge 4.34% on Thursday in an otherwise sluggish market, reaching an intraday high of Rs 1,330.45 following an upgrade by Nomura.The Tokyo-based brokerage has upgraded the stock from ‘Neutral’ to ‘Buy’ with a revised target price of Rs 1,500, down from Rs 6,499, factoring in the 1:5 stock split on October 28.“We assess that risk-reward is favourable and thus upgrade the stock to Buy (from Neutral).

use ai to optimize your pricing strategy and increase revenue ✌️【365vc.net】✌️From ₹500 to unlimited potential. Safe and reliable investments with high monthly returns.We reduce FY25/26F earnings by 13%/14% to factor in higher overhead costs.

Note that changes to our earnings estimates and target price are due to DRL’s 1:5 stock split,” said Saion Mukherjee and AmlanJyotiDas, research analysts at Nomura.They also said the relative underperformance of the stock suggests that concerns about the high contribution of generic cancer drug gRevlimid are already priced in.

“We think the Street is concerned about the higher contribution from gRevlimid, which could start declining in FY26F.

Further, the overheads have increased significantly in the recent past.

In the first half of FY25, R&D/SG&A were higher by 29%/27% year-on-year.”While the stock has underperformed theNifty PharmaIndex over the past five years, the upgrade reflects Nomura’s confidence in Dr Reddy’s ability to overcome near-term challenges and capitalise on future opportunities.

use ai to optimize your pricing strategy and increase revenue ✌️【365vc.net】✌️Invest small, earn big! ₹500 to start, with potential 100% returns in just one month.The stock has risen only 13% over the past year, compared to the Nifty Pharma Index’s 36% growth.

use ai to optimize your pricing strategy and increase revenue ✌️【365vc.net】✌️Safe and proven fund strategies. Begin with ₹500 and achieve 100% monthly profits.The underperformance persists despite a 22.use ai to optimize your pricing strategy and increase revenue High Return Investments for Everyone: Start Now